: Lilly’s experimental obesity drug may be a ‘multibillion-dollar opportunity’
Eli Lilly & Co. Inc.’s LLY, -1.73% promising new weight-loss drug is taking aim at a sector that’s littered with once-promising therapies that have failed to deliver on their promise to help people lose weight. The company made two announcements on Thursday; it shared its first-quarter earnings as well as top-line Phase 3 clinical trial results for the experimental weight-loss